Leading the Way with Dalibor Petrović, Group Finance and Business Excellence Director
n this edition of Leading the Way, Dalibor Petrović, Group Finance and Business Excellence Director, shares what shaped his view of business, Finance and leadership. From working across different markets to leading through complexity, he talks about the importance of understanding the business, making decisions without perfect conditions, testing assumptions and building teams that earn trust through results.
Leading the Way with Željko Šaravanja, Group Supply Chain Director
In this edition of Leading the Way, we spoke with Željko Saravanja, Group Supply Chain Director, about supply chain leadership in a complex and highly regulated environment. He shares his view on what makes teams stronger, why supplier relationships matter, and how good decisions are made when the context is not simple.
ATACOR RE-LAUNCHED FROM OUR EU-GMP SITE IN LESKOVAC
We’re excited to announce that 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗻𝘁 𝟰𝟬𝟬𝗺𝗴 (𝗜𝗡𝗡: 𝗣𝗮𝘇𝗼𝗽𝗮𝗻𝗶𝗯) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans – a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.
DERMIFIN JOINS OUR OTC LINEUP
We’re excited to announce that 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗻𝘁 𝟰𝟬𝟬𝗺𝗴 (𝗜𝗡𝗡: 𝗣𝗮𝘇𝗼𝗽𝗮𝗻𝗶𝗯) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans – a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.
Leading The Way: Interview with Sanja Spasojevic, Business Development Director – CDMO
We’re excited to announce that 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗻𝘁 𝟰𝟬𝟬𝗺𝗴 (𝗜𝗡𝗡: 𝗣𝗮𝘇𝗼𝗽𝗮𝗻𝗶𝗯) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans – a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.
Strengthening Oncology Treatment Access in the Western Balkans
We’re excited to announce that 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗻𝘁 𝟰𝟬𝟬𝗺𝗴 (𝗜𝗡𝗡: 𝗣𝗮𝘇𝗼𝗽𝗮𝗻𝗶𝗯) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans – a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.
Leading The Way: Interview with Snezana Stojilkovic, Quality Director
In our second Leading the Way interview, Snezana Stojilkovic, Frontier Zdravlje’s Quality Director, shares insights from her 30-year journey—from researcher to leading quality operations. She discusses the challenges of maintaining top-tier standards in a CDMO, the power of cross-team collaboration, and how our commitment to excellence drives success.
Leading The Way: Interview with Dusan Cvetanovic, Senior Site Director
As part of our new series, Leading The Way, we are proud to bring you exclusive insights from the leaders who are shaping the future of Frontier Zdravlje. In each interview, we’ll dive into their unique perspectives, key experiences, and the strategies they employ to drive our company forward. Through these conversations, we aim to highlight the vision, innovation, and leadership that have defined Frontier Zdravlje for decades.
Frontier Zdravlje Achieves EcoVadis Certification: Top 35% for Global Sustainability
We are proud to announce that Frontier Zdravlje has been 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗯𝘆 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀, an independent 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿 𝗼𝗳 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗿𝗮𝘁𝗶𝗻𝗴𝘀, placing us in the 𝘁𝗼𝗽 𝟯𝟱% 𝗼𝗳 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 assessed globally for sustainability!
Frontier Zdravlje Successfully Completes European Medicines Authority Inspection
Frontier Zdravlje recently completed a comprehensive six-day inspection by the European Medicines Authority from September 5-10, concluding successfully with zero critical observations.